Trial Profile

A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SBT 020 (Primary)
Indications Huntington's disease
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Acronyms CHALLENGE-HD
Sponsors Mighty Therapeutics; Stealth BioTherapeutics

Most Recent Events

16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
16 Nov 2020 Results published in the British Journal of Clinical Pharmacology
01 Feb 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com